IFN-alpha-2b vs Mifamurtide
Head-to-head comparison of IFN-alpha-2b (Recombinant human interferon alfa-2b) and Mifamurtide (Muramyl Tripeptide Phosphatidylethanolamine) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | IFN-alpha-2b | Mifamurtide |
|---|---|---|
| Category | Immune Support | Immune Support |
| Full Name | Recombinant human interferon alfa-2b | Muramyl Tripeptide Phosphatidylethanolamine |
| Molecular Weight | ~19,300 Da | N/A |
| Half-Life | 2-8 hours | 2-4 h |
| Amino Acids | 165 | N/A |
| Typical Dose | 3-10 million IU | 2 mg/m2 |
| Route | Subcutaneous/Intramuscular | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 2000 | 150 |
| Research Status | Clinical | Clinical |
IFN-alpha-2b Benefits
- ✓broad antiviral signaling
- ✓innate immune activation
- ✓reduced viral replication
- ✓clinical immunomodulation
Mifamurtide Benefits
- ✓macrophage-activation
- ✓innate-immune-signaling
- ✓immune-adjuvant-research
- ✓cytokine-response
IFN-alpha-2b Dosing
3-10 million IU per dose|Subcutaneous or intramuscular administration|Monitor CBC, liver enzymes, and mood
Mifamurtide Dosing
2 mg/m2 IV|2x weekly for 12 weeks|then weekly for 24 weeks in approved regimens
IFN-alpha-2b Side Effects
- ⚠flu-like symptoms
- ⚠depression or mood changes
- ⚠cytopenias
Mifamurtide Side Effects
- ⚠fever/chills
- ⚠fatigue
- ⚠nausea
Research Overview
IFN-alpha-2b
Extensively studied recombinant type I interferon with direct antiviral and immunoregulatory effects. Clinical literature spans hepatitis treatment, antiviral research, and immune-oncology contexts.
Mifamurtide
Mifamurtide has substantial literature as an innate immune activator and is an approved oncology adjunct in some regions. Research centers on NOD-like receptor signaling, macrophage activation, and downstream cytokine effects.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.